½ÃÀ庸°í¼­
»óǰÄÚµå
1285016

¼¼°èÀÇ ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ¼Ö·ç¼Ç ½ÃÀå Àü¸Á(-2027³â)

Global Continuous Glucose Monitoring Solutions Market, 2027 Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Frost & Sullivan | ÆäÀÌÁö Á¤º¸: ¿µ¹® 77 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º» º¸°í¼­´Â ¼¼°è ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM, Continuous Glucose Monitoring) ¼Ö·ç¼Ç ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ, °æÀï ±¸µµ, ±â¼ú µ¿Çâ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Àü·«Àû Çʼö¿ä°Ç

  • ¼ºÀåÀÌ ´õ¿í ¾î·Á¿öÁö´Â ÀÌÀ¯
  • The Strategic Imperative 8(TM)
  • ¼¼°èÀÇ Áö¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ¼Ö·ç¼Ç ¾÷°è¿¡ ´ëÇÑ »óÀ§ 3°³ Àü·«Àû Çʼö¿ä°ÇÀÇ ¿µÇâ
  • ¼ºÀå ±âȸ°¡ Growth Pipeline Engine(TM)À» °¡¼Ó

¼ºÀå ±âȸ ºÐ¼®

  • ºÐ¼® ¹üÀ§
  • ¼¼ºÐÈ­
  • ¼¼°èÀÇ ´ç´¢º´ ºÎ´ã
  • ´ç´¢º´¿ë µð¹ÙÀ̽º
  • ÁÖ¿ä °æÀï
  • ¼ºÀå ÁöÇ¥
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ¿¹ÃøÀÇ ÀüÁ¦Á¶°Ç
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°
  • ¸ÅÃâ ¿¹Ãø : Áö¿ªº°
  • ¸ÅÃâ ¿¹Ãø ºÐ¼®
  • ¸ÅÃâ ¿¹Ãø ºÐ¼® : Áö¿ªº°
  • °¡°Ý µ¿Çâ°ú ¿¹Ãø ºÐ¼®
  • CGM µð¹ÙÀ̽º : ÄÄÆ÷³ÍÆ®º°
  • °æÀï ȯ°æ
  • ¸ÅÃâ Á¡À¯À²
  • ¸ÅÃâ Á¡À¯À² ºÐ¼®
  • CGM ¼Ö·ç¼Ç - ÁÖ¿ä º¥´õÀÇ Á¸Àç°¨ : Áö¿ªº°

Áö¿ª ¹× ±¹°¡º° ±âȸ ºÐ¼®

  • Áö¿ªº° ´ç´¢º´ Á¡À¯À² º¯È­
  • CGM ¼Ö·ç¼Ç - ´ç´¢º´ : Áö¿ªº°
  • Áß±¹
  • Àεµ
  • »ç¿ìµð¾Æ¶óºñ¾Æ

CGM TAM

  • ÃÖÁ¾»ç¿ëÀÚ - CGM
  • ´ç´¢º´ »ç¿ëÀÚ
  • ´ç´¢º´ Àü´Ü°è
  • ¿îµ¿¼±¼ö ¹× ÇÇÆ®´Ï½º °ü¸®
  • À£´Ï½º - üÁß °ü¸®
  • ÃÖÁ¾»ç¿ëÀÚ - °³¿ä

»õ·Î¿î ºñÁî´Ï½º ¸ðµ¨°ú ±â¼ú

  • »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨
  • ºñħ½À ¸ð´ÏÅ͸µ ±â¼ú

¼ºÀå ±âȸ ºÐ¼® - ȨÄɾî ȯ°æ

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø : Áö¿ªº°
  • ¿¹Ãø ºÐ¼®

¼ºÀå ±âȸ ºÐ¼® - º´¿ø, ±âŸ Äɾî ȯ°æ

  • ¼ºÀå ÁöÇ¥
  • ¸ÅÃâ ¿¹Ãø
  • ¸ÅÃâ ¿¹Ãø : Áö¿ªº°
  • ¿¹Ãø ºÐ¼®

¼ºÀå ±âȸ

  • ¼ºÀå ±âȸ 1: ´ç´¢º´ ¹× ¸¸¼º Áúȯ ¼Ö·ç¼Ç Á¦°ø¾÷ü¿ÍÀÇ ÆÄÆ®³Ê½Ê
  • ¼ºÀå ±âȸ 2 : º´¿ø
  • ¼ºÀå ±âȸ 3 : À£´Ï½º ¹× ºñ´ç´¢º´ ¾ÖÇø®ÄÉÀ̼Ç
  • ¼ºÀå ±âȸ 4 : ½ÅÈï ½ÃÀå

´ÙÀ½ ´Ü°è

LSH 23.06.13

Opportunities in Type 2 Diabetic and Non diabetic Patients Treatment Boost Future Growth Potential

The rising prevalence of diabetes entails a greater need for treatment and monitoring. In this context, multiple growth opportunities arise in the continuous glucose monitoring (CGM) solutions market. CGM devices have been extensively used for Type 1 diabetes patients. With further technological development and clinical studies, CGM's applications expand toward Type 2 diabetes, prediabetes, weight management, nutrition tracking, and metabolic health tracking.

Most Type 1 diabetes patients-the main users of CGM-do not use these solutions due to their high costs and low reimbursements, especially in low- and middle-income countries. The adoption of these devices is very low in Asia-Pacific, Latin America, and the Middle East and Africa due to low accessibility, awareness, and affordability. A vast patient pool of diabetic and prediabetic patients needing treatment in these regions creates attractive opportunities for CGM vendors.

Vendors in the CMG solutions industry are partnering with various players across the diabetes treatment ecosystem to increase CGM adoption, data integration, and device combability. Examples of these partnerships are common between CGM vendors and insulin pen, insulin pump, and diabetes management platform providers. Technological advancements and strategic partnerships create new opportunities for CGM vendors.

Research Highlights:

  • Market size by revenue, covering historic and forecast data by segment (Homecare and Other Care Settings) and region (North America, Europe, Asia-Pacific, and the rest of the world)
  • Market drivers and restraints
  • Competitive landscape, including company market share analysis
  • Market opportunity size and new business models
  • Technological trends and growth opportunities for stakeholders

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Continuous Glucose Monitoring Solutions Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of Analysis
  • Segmentation
  • Global Burden of Diabetes
  • Diabetes Devices
  • Key Competitors
  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast by End User
  • Revenue Forecast by Region
  • Revenue Forecast Analysis
  • Revenue Forecast Analysis by Region
  • Pricing Trends and Forecast Analysis
  • CGM Devices by Components
  • Competitive Environment
  • Revenue Share
  • Revenue Share Analysis
  • CGM Solutions-Key Vendor Presence by Region

Regional and Country Opportunities Analysis

  • Changes in Regional Share of Diabetes
  • CGM Solutions-Diabetes by Region
  • China
  • India
  • Saudi Arabia

Total Addressable Market for CGM

  • End Users-CGM
  • Diabetic Users
  • Prediabetes
  • Athletes and Fitness Management
  • Wellness-Weight Management
  • End Users-Summary

New Business Models and Technologies

  • New Business Models
  • Noninvasive Monitoring Technologies

Growth Opportunity Analysis-Homecare Settings

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Opportunity Analysis-Hospitals and Other Care Settings

  • Growth Metrics
  • Revenue Forecast
  • Revenue Forecast by Region
  • Forecast Analysis

Growth Opportunity Universe

  • Growth Opportunity 1: Partnerships with Diabetes and Chronic Disease Solutions Providers
  • Growth Opportunity 2: Hospitals
  • Growth Opportunity 3: Wellness and Nondiabetic Applications
  • Growth Opportunity 4: Emerging Markets

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦